{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T07:40:58Z","timestamp":1685950858831},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.eimc.2010.12.001","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T17:58:43Z","timestamp":1297879123000},"page":"535-544","source":"Crossref","is-referenced-by-count":6,"title":["Manejo de la toxicidad por f\u00e1rmacos antirretrovirales"],"prefix":"10.1016","volume":"29","author":[{"given":"Pere","family":"Domingo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2010.12.001_bib0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","article-title":"Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na\u00efve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Na\u00efve Patients","volume":"14","author":"D\u2019Arminio Monforte","year":"2000","journal-title":"AIDS AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","article-title":"Understanding and managing the adverse effects of antirretroviral therapy","volume":"85","author":"Hawkins","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.eimc.2010.12.001_bib0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00002030-199903110-00013","article-title":"Incidence of rash and discontinuation of nevirapine using two different escalating initial doses","volume":"13","author":"Ant\u00f3n","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543784.5.9.1183","article-title":"A review of its development, pharmacological profile and potential for clinical use","volume":"5","author":"Murphy","year":"1996","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.eimc.2010.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"23","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.eimc.2010.12.001_bib0030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","article-title":"Abacavir hypersensitivity reaction","volume":"34","author":"Hewitt","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0035","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.12.001_bib0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","article-title":"Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort","volume":"34","author":"O\u2019Brien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0045","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","article-title":"Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals","volume":"143","author":"Clifford","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2010.12.001_bib0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1310\/92VR-FP24-J8GA-B49Q","article-title":"Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients","volume":"6","author":"Hawkins","year":"2005","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2010.12.001_bib0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","article-title":"Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence","volume":"38","author":"Fumaz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0060","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0065","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-151-3-200908040-00127","article-title":"Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events. A randomized trial","volume":"151","author":"Guti\u00e9rrez-Valencia","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2010.12.001_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2010.12.001_bib0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.qai.0000221683.44940.62","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs","volume":"42","author":"Maida","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0085","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1086\/603559","article-title":"Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: A Nested Case-Control Study","volume":"49","author":"Kovari","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus (HCV). 2007 updated recommendations from the HIV-HCV International Panel","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0095","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/339041","article-title":"Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature","volume":"34","author":"Falc\u00f3","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1157\/13077376","article-title":"Tratamiento de la hiperlactatemia sintom\u00e1tica y de la acidosis l\u00e1ctica en pacientes con infecci\u00f3n por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa an\u00e1logos de los nucle\u00f3sidos","volume":"125","author":"Pedrol","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2010.12.001_bib0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1529-8027.2001.006001014.x","article-title":"Peripheral neuropathy and antirretroviral drugs","volume":"6","author":"Dalakas","year":"2001","journal-title":"Peripher Nerv Syst"},{"key":"10.1016\/j.eimc.2010.12.001_bib0115","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00002030-200211080-00002","article-title":"HIV-associated sensory neuropathies","volume":"16","author":"Keswani","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0120","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.WNL.0000063304.88470.D9","article-title":"Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial","volume":"60","author":"Simpson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.eimc.2010.12.001_bib0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1468-1293.2008.00658.x","article-title":"Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection","volume":"10","author":"Valcour","year":"2009","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2010.12.001_bib0130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","article-title":"Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor\u2013based highly active antiretroviral therapy in HIV-1\u2013infected patients with undetectable plasma HIV-1\u2013RNA","volume":"15","author":"Clumeck","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0135","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/340312","article-title":"A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection","volume":"185","author":"Opravil","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1310\/EJRF-JGGH-GRCD-MED8","article-title":"Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study","volume":"4","author":"Lafeuillade","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.eimc.2010.12.001_bib0145","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.aids.0000171405.46113.bf","article-title":"Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine","volume":"19","author":"Fisac","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00002030-200207050-00010","article-title":"Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine","volume":"16","author":"Negredo","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/0889222041217374","article-title":"Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection","volume":"20","author":"Tebas","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.eimc.2010.12.001_bib0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/340863","article-title":"Long-term metabolic consequences of switiching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus\u2013infected patients with lipoatrophy","volume":"35","author":"Estrada","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0170","unstructured":"Rachlis A, Becker S, Gill J, et al. Successful substitution of protease inhibitors with SUSTIVA (efavirenz) in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomized, multicenter, open label study (DMP 266-049) [abstract 475]. En: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology; 2000."},{"key":"10.1016\/j.eimc.2010.12.001_bib0175","unstructured":"Katlama C, Staszewski S, Cluck N, et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open label study (DMP 006-027) [abstract LbPeB7044]. En: Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa). Rome: International AIDS Society; 2000. p. 283."},{"key":"10.1016\/j.eimc.2010.12.001_bib0180","unstructured":"Martinez E, Romeu J, Garcia-Viejo A, et al. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1\u2013infected patients with lipodystrophy [abstract 668]. En: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health; 2001."},{"key":"10.1016\/j.eimc.2010.12.001_bib0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor\u2013experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"Ruiz","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0190","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200005050-00006","article-title":"Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under longterm successful triple combination therapy","volume":"14","author":"Barreiro","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0195","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label multicentre study","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0200","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2010.12.001_bib0205","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/01.aids.0000131343.53419.04","article-title":"Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results","volume":"18","author":"Domingo","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2010.12.001_bib0215","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00126334-200112010-00016","article-title":"Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1\u2013positive persons: single arm observational cohort","volume":"28","author":"Moyle","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0225","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2165\/00003088-200241140-00004","article-title":"Interactions between antiretroviral drugs used for the therapy of the metabolic complications encountered during HIV infection","volume":"41","author":"Fichtenbaum","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2010.12.001_bib0230","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2010.12.001_bib0235","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-010-0047-3","article-title":"Abacavir and cardiovascular risk: reviewing the evidence","volume":"7","author":"Costagliola","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.eimc.2010.12.001_bib0245","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486\u2013524.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.eimc.2010.12.001_bib0250","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/QAD.0b013e32832d3b85","article-title":"Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study","volume":"23","author":"Grunfeld","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tips.2004.12.005","article-title":"Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: the adipocyte as a target of antiretroviral-induced mitochondrial toxicity","volume":"26","author":"Giralt","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.eimc.2010.12.001_bib0260","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1517\/14656566.8.12.1871","article-title":"Strategies in the treatment of HIV-1-associated adipose redistribution syndromes","volume":"12","author":"Gutierrez","year":"2007","journal-title":"Expert Opinion Pharmacother"},{"key":"10.1016\/j.eimc.2010.12.001_bib0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)","volume":"13","author":"Slama","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.eimc.2010.12.001_bib0270","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0b013e32833ea9bc","article-title":"Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229","volume":"24","author":"McComsey","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0275","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eimc.2009.05.004","article-title":"Valoraci\u00f3n y manejo de la nefropat\u00eda en el paciente con infecci\u00f3n por VIH-1: Una revisi\u00f3n pr\u00e1ctica","volume":"28","author":"Domingo","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2010.12.001_bib0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/QAI.0b013e3181d05579","article-title":"Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men","volume":"55","author":"Wever","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2010.12.001_bib0285","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1086\/367566","article-title":"Emerging bone problems in patients infected with human immunodeficiency virus","volume":"36","author":"Mondy","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0290","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2010.12.001_bib0295","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0b013e328334344e","article-title":"High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome","volume":"24","author":"Worm","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0300","unstructured":"Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine (ddI) absorption in HIV-infected patients [abstract #A-498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois."},{"key":"10.1016\/j.eimc.2010.12.001_bib0305","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(99)00593-0","article-title":"Sexual dysfunction with protease inhibitors","volume":"353","author":"Martinez","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2010.12.001_bib0310","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2710.1996.tb00006.x","article-title":"Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction","volume":"21","author":"Bruckert","year":"1996","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.eimc.2010.12.001_bib0315","doi-asserted-by":"crossref","first-page":"F101","DOI":"10.1097\/00002030-199910220-00001","article-title":"Interaction of sildenafil and indinavir when co-administered to HIV-positive patients","volume":"13","author":"Merry","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2010.12.001_bib0320","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-199957060-00015","article-title":"A review of its use in erectile dysfunction","volume":"57","author":"Langtry","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2010.12.001_bib0325","first-page":"15","article-title":"Pharmacogenetics of adverse effects due to antiretroviral treatments","volume":"12","author":"Vidal","year":"2010","journal-title":"AIDS Rev"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10004374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10004374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T07:08:10Z","timestamp":1685948890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X10004374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0213005X10004374"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2010.12.001","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}